Roles of PD-1/PD-L1 immune checkpoint in thyroid diseases
10.3760/cma.j.cn321828-20211019-00363
- VernacularTitle:PD-1/PD-L1免疫检查点在甲状腺疾病中的作用
- Author:
Guoqiang ZHANG
1
;
Quanyong LUO
Author Information
1. 上海交通大学附属第六人民医院核医学科，上海 200233
- Keywords:
Thyroid diseases;
Immune checkpoint inhibitors;
Programmed cell death 1 receptor;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(2):118-121
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death receptor 1 (PD-1)/PD-1 ligand (PD-L1) maintains immune tolerance of normal tissues and mediates immune escape of tumors. For autoimmune thyroiditis, thyroid follicular epithelial cells inhibit the damage of T cells by up-regulating PD-L1 expression. With the application of immune checkpoint inhibitors (ICIs) in the field of cancer therapy, the incidence of immune-related thyroid disorders caused by ICIs has increased. Thyroid function should be monitored during and after ICIs treatment to promptly diagnose primary and (or) secondary thyroid disorders. The PD-1/PD-L1 signaling directly stimulates thyroid cancer cells, and exerts inhibitory effects on tumor-infiltrating immune cells. Combination of ICIs targeting PD-1/PD-L1 with chemo-radiotherapy or targeted therapy is a promising therapeutic strategy in the treatment of refractory thyroid cancers.
